Claims for Patent: 10,188,692

Summary for Patent: 10,188,692

Title:	Methods and compositions for preventing or treating ophthalmic conditions
Abstract:	The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Inventor(s):	Liu; Liping (Manassas, VA), Tang; Shibo (Guangzhou, CN), Liang; Xiaoling (Guangzhou, CN)
Assignee:	Stealth Biotherapeutics Corp (Monaco, MC)
Application Number:	15/401,527
Patent Claims:	1. A method for treating macular degeneration in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide represented by the formula D-Arg-2'6'-Dmt-Lys-Phe-NH2 or Phe-D-Arg-Phe-Lys-NH2, where the subject has drusen. 2. The method of claim 1, wherein the peptide is D-Arg-2'6'-Dmt-Lys-Phe-NH.sub.2. 3. The method of claim 1, wherein the peptide is Phe-D-Arg-Phe-Lys-NH.sub.2. 4. The method of claim 1, wherein the subject is a human. 5. The method of claim 1, wherein the peptide is administered intraocularly, iontophoretically, orally, topically, systemically, intravenously, subcutaneously, or intramuscularly. 6. The method of claim 1 further comprising separately, sequentially, or simultaneously administering a second active agent. 7. The method of claim 6, wherein the second active agent is selected from the group consisting of: an antioxidant, a metal complexer, an anti-inflammatory drug, an antibiotic, and an antihistamine. 8. The method of claim 7, wherein the antioxidant is vitamin A, vitamin C, vitamin E, lycopene, selenium, .alpha.-lipoic acid, coenzyme Q, glutathione, or a carotenoid. 9. The method of claim 6, wherein the second active agent is selected from the group consisting of: aceclidine, acetazolamide, anecortave, apraclonidine, atropine, azapentacene, azelastine, bacitracin, befunolol, betamethasone, betaxolol, bimatoprost, brimonidine, brinzolamide, carbachol, carteolol, celecoxib, chloramphenicol, chlortetracycline, ciprofloxacin, cromoglycate, cromolyn, cyclopentolate, cyclosporin, dapiprazole, demecarium, dexamethasone, diclofenac, dichlorphenamide, dipivefrin, dorzolamide, echothiophate, emedastine, epinastine, epinephrine, erythromycin, ethoxzolamide, eucatropine, fludrocortisone, fluorometholone, flurbiprofen, fomivirsen, framycetin, ganciclovir, gatifloxacin, gentamycin, homatropine, hydrocortisone, idoxuridine, indomethacin, isoflurophate, ketorolac, ketotifen, latanoprost, levobetaxolol, levobunolol, levocabastine, levofloxacin, lodoxamide, loteprednol, medrysone, methazolamide, metipranolol, moxifloxacin, naphazoline, natamycin, nedocromil, neomycin, norfloxacin, ofloxacin, olopatadine, oxymetazoline, pemirolast, pegaptanib, phenylephrine, physostigmine, pilocarpine, pindolol, pirenoxine, polymyxin B, prednisolone, proparacaine, ranibizumab, rimexolone, scopolamine, sezolamide, squalamine, sulfacetamide, suprofen, tetracaine, tetracyclin, tetrahydrozoline, tetryzoline, timolol, tobramycin, travoprost, triamcinulone, trifluoromethazolamide, trifluridine, trimethoprim, tropicamide, unoprostone, vidarbine, xylometazoline, pharmaceutically acceptable salts thereof, and combinations thereof.

Details for Patent 10,188,692

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2029-08-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2029-08-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2029-08-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2029-08-24